VERACYTE, INC. Form 3 October 29, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB APPROVAL** FORM 3 Washington, D.C. 20549 OMB Number: **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** Expires: **SECURITIES** Estimated average burden hours per Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement VERACYTE, INC. [VCYT] TPG Group Holdings (SBS) (Month/Day/Year) Advisors, Inc. 10/29/2013 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O TPG GLOBAL, LLC, 301 (Check all applicable) COMMERCE STREET, SUITE 3300 _X_ 10% Owner Director (Street) Officer Other 6. Individual or Joint/Group (give title below) (specify below) Filing(Check Applicable Line) Form filed by One Reporting Person FORT WORTH. TXÂ 76102 _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities

Beneficially Owned

(Instr. 4)

1. Title of Security (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

(Instr. 5)

3.

Ownership

SEC 1473 (7-02)

Form: Direct (D) or Indirect (I)

4. Nature of Indirect Beneficial

Ownership

(Instr. 5)

3235-0104 January 31, 2005 0.5

Edgar Filing: VERACYTE, INC. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A Convertible Preferred Stock	(5)	(5)	Common Stock	1,758,333	\$ <u>(5)</u>	Ι	See Explanation of Responses (1) (2) (3) (4)
Series B Convertible Preferred Stock	(5)	(5)	Common Stock	1,004,000	\$ <u>(5)</u>	Ι	See Explanation of Responses (1) (2) (3) (4)
Series C Convertible Preferred Stock	(5)	(5)	Common Stock	789,596	\$ <u>(5)</u>	Ι	See Explanation of Responses (1) (2) (3) (4)

Reporting Owners

Reporting Owner Name / Address	Relationships				
hepoting of the Funct Fluites	Director	Director 10% Owner		Officer Other	
TPG Group Holdings (SBS) Advisors, Inc. C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102	Â	X	Â	Â	
BONDERMAN DAVID C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102	Â	X	Â	Â	
COULTER JAMES G C/O TPG GLOBAL, LLC 301 COMMERCE STREET, SUITE 3300 FORT WORTH, TX 76102	Â	X	Â	Â	

Signatures

/s/ Ronald Cami, Vice President, TPG Group Holdings (SBS) Advisors, Inc. (6)	10/29/2013	
**Signature of Reporting Person	Date	
/s/ Ronald Cami on behalf of David Bonderman (6)(7)		
**Signature of Reporting Person	Date	
/s/ Ronald Cami on behalf of James G. Coulter (6)(7)		
<u>**</u> Signature of Reporting Person	Date	

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) David Bonderman and James G. Coulter are officers and sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. ("Group Advisors" and, together with Messrs.

Edgar Filing: VERACYTE, INC. - Form 3

Bonderman and Coulter, the "Reporting Persons"), which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnology GenPar II Advisors, LLC, which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the general partner of TPG Biotechnology GenPar II, L.P., which is the ge

(2) partner of TPG Biotechnology Partners II, L.P. ("TPG Biotech II"), which directly holds 7,033,333 shares of Series A Convertible Preferred Stock (the "Series A Preferred") of Veracyte, Inc. (the "Issuer"), 4,016,000 shares of Series B Convertible Preferred Stock (the "Series B Preferred") of the Issuer and 3,158,385 shares of Series C Convertible Preferred Stock (the "Series C Preferred" and, together with the Series A Preferred and the Series B Preferred, the "Preferred Stock") of the Issuer.

Because of the relationship between the Reporting Persons and TPG Biotech II, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech II. Each of TPG Biotech II and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech II's or such Reporting Person's pecuniary interest therein, if any.

Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be
(4) deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Pursuant to the Fourth Amended and Restated Certificate of Incorporation of the Issuer, as amended, the shares of Series A Preferred,

(5) Series B Preferred and Series C Preferred are convertible, at the option of the holder, at any time into shares of Common Stock, par value \$0.001 per share, of the Issuer, at initial conversion rates in each case equal to one share of Common Stock per share of Preferred Stock. The initial conversion rates have been adjusted as a result of a 1-for-4 reverse stock split of the Issuer's Common Stock.

Â

Remarks:

(6) The Reporting Persons are jointly filing this Form 3 pursuant to Rule 16a-3(j) under the Excha

(7) Ronald Cami is signing on behalf of both Messrs. Bonderman and Coulter pursuant to the aut

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.